

TITULO	REVISTA	FI	Q/D	DOI	Pubmed Id	UT (Unique WOS ID)
Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry	CANCER MEDICINE	4,0	2	10.1002/cam4.6120	37212507	WOS:000993402700001
Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era	BONE MARROW TRANSPLANTATION	4,8	1	10.1038/s41409-023-01949-x	36918682	WOS:000951211500001
Expert opinion paper on the treatment of hemophilia A with emicizumab	HEMATOLOGY	1,9	4	10.1080/16078454.2023.2166334	36636993	WOS:000915277100001
Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia	HEMASPHERE	9,1	1	10.1097/HS9.0000000000000936	37476303	WOS:001030663100001
Assessment of joint bleeding and target joints in patients with severe or moderately severe hemophilia B (factor IX \leq 2%) receiving prophylaxis with rIX-FP in the PROLONG-9FP clinical trial program	EUROPEAN JOURNAL OF HAEMATOLOGY	3,1	3	10.1111/ejh.14010	37232041	WOS:000995226700001
von Willebrand factor neutralizing and non-neutralizing alloantibodies in 213 subjects with type 3 von Willebrand disease enrolled in 3WINTERS-IPS	JOURNAL OF THROMBOSIS AND HAEMOSTASIS	1,4	D1	10.1016/j.jtha.2023.01.001	36792472	WOS:001054743100001
High Rate of Inappropriate Antibiotics in Patients with Hematologic Malignancies and Pseudomonas aeruginosa Bacteremia following International Guideline Recommendations	MICROBIOLOGY SPECTRUM	3,7	2	10.1128/spectrum.00674-23	37367629	WOS:001017116000001
Health-related quality of life following valoctocogene roxaparovec gene therapy for severe hemophilia A in the phase 3 trial GENER8-1	JOURNAL OF THROMBOSIS AND HAEMOSTASIS	5,5	1	10.1016/j.jtha.2023.08.032	37678546	WOS:001125013700001
Immune thrombotic thrombocytopenic purpura in older patients: Results from the Spanish TTP Registry (REPTT)	BRITISH JOURNAL OF HAEMATOLOGY	6,5	1	10.1111/bjh.19109	37723363	WOS:001069292800001
Two-Year Outcomes of Valoctocogene Roxaparovec Therapy for Hemophilia A	NEW ENGLAND JOURNAL OF MEDICINE	158,5	D1	10.1056/NEJMoa2211075	36812433	WOS:001079845600010
Treatment of high-risk bleeding with susoctocog alfa in a patient with acquired haemophilia A and a nosocomial severe acute respiratory syndrome coronavirus 2 infection	EUROPEAN JOURNAL OF HOSPITAL PHARMACY	1,7	4	10.1136/ejpharm-2021-002805	34011555	WOS:000728294800001